SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is experiencing heightened volatility and community speculation, with investors tracking options flow and potential gamma exposure as the stock tests key technical levels. While discussions remain centered on the prospect of a short squeeze and long-term turnaround efforts, the community is actively debating whether upcoming corporate actions or market technicals will act as the catalyst for sustained upward momentum.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending as investors position for a potential short squeeze ahead of its upcoming earnings report, with the community highlighting high borrow rates and limited share availability. Bullish sentiment is being driven by speculation regarding potential partnerships and the strategic value of recent acquisitions, leading retail traders to advocate for holding positions to put pressure on short sellers.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is seeing intense trading activity as investors react to a private placement and a new licensing deal for its anti-IgE asset, leading to speculation about a potential short squeeze. The community remains divided, with some traders targeting significant upside from the company's clinical pipeline, while others warn of volatility and structural risks following a recent reverse stock split.

AIOS Tech, Inc. is an investment holding company, which engages in the provision of financing solutions to small- and mid-size enterprises. The company was founded on May 29, 2012 and is headquartered in Shanghai, China.

AIOS Tech Inc. - Ordinary Shares - Class A

AIOS Tech Inc.

AIOS is trending due to significant volatility and volume, with the community actively debating whether the stock is a prime candidate for a short squeeze or a potential pump-and-dump trap linked to share dilution concerns. Traders are closely watching micro-float dynamics and pivot points as the stock maintains heavy interest from day traders seeking momentum plays.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is experiencing significant volatility as investors digest a massive earnings beat and a newly announced six-billion-dollar share buyback, leading to a surge in bullish analyst price target revisions. While some are treating the stock's recent parabolic rally as a sell-the-news event, the community remains intensely divided between those betting on a sustained AI-driven memory supercycle and those calling for a sharp correction from current highs.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining attention as traders speculate on potential price action and volatility ahead of the Juneteenth period, a timeframe that has historically triggered significant speculative momentum in the stock. Community discussion is currently centered on these seasonal trends, low float dynamics, and persistent interest in the stock's potential for sudden, volume-driven swings.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending as investors weigh significant concerns over executive compensation and financial internal controls against the potential of new international contracts. The community remains divided between skepticism regarding management's communication style and bullish sentiment focused on the company's long-term integration into modern defense procurement.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWM is seeing heightened volatility as investors grapple with conflicting signals from geopolitical tensions and ongoing sector rotation. While small caps exhibit price resilience, market participants are actively debating whether these levels represent sustainable momentum or a precarious build-up before a broader market pivot.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently trending as investors focus on the company's BLA submission for its lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is actively debating the significance of recent partnership news and management's strategy, with sentiment divided between those anticipating a major revaluation following FDA milestones and those concerned about the company's cash burn and competitive positioning.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is currently trending following a strong earnings report and the announcement of a new value menu launching in April, which aims to regain its reputation for affordability amid high consumer sensitivity to prices. Investors are closely monitoring how this strategy impacts traffic and margins, while community sentiment remains divided between those viewing the company as a durable defensive value play and those skeptical of the brand's long-term quality and leadership.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer PR Newswire AUSTIN...

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Genprex Collaborators to...

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting

Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene Therapy To Be Released at the 2026 ASCO Annual Meeting Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa Gene...

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy

Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa Gene Therapy Genprex Signs Sponsored Research Agreement to Study Biomarkers that May...

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators Present Positive...

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Genprex Collaborators to Present...

Genprex to Participate at BIO Europe Spring 2026

Genprex to Participate at BIO Europe Spring 2026 Genprex to Participate at BIO Europe Spring 2026 PR Newswire AUSTIN, Texas, March 10, 2026 AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc...

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa Gene Therapy in Combination with Immunotherapies to Treat Cancer Genprex Strengthens Intellectual Property...

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034)  DelveInsight

EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast...

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2...

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

GNPX
Genprex Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GNPX News

GNPXGenprex Inc